Abstract
We give an overview of the huge and increasing economic costs of dementia, both for the persons with dementia and for society as a whole. Public intervention is needed if we want to provide affordable and high-quality care to all persons with dementia. First, although an effective pharmaceutical cure for dementia would undoubtedly be a blockbuster drug for private companies, economic features of the production process of dementia medicines explain the relative underinvestment in private research. Second, there are no well-functioning private insurance markets for long-term care expenditures. Public intervention is needed to stimulate research, to finance care, to reduce inequalities in health and well-being, and address barriers to access to effective treatment and supportive care.
Original language | English |
---|---|
Title of host publication | Dementia and Society |
Editors | Mathieu VANDENBULCKE, Rose-Marie DRÖES, Erik SCHOKKAERT |
Place of Publication | Cambridge |
Publisher | Cambridge University Press |
Pages | 267-289 |
Number of pages | 23 |
ISBN (Electronic) | 9781108918954 |
ISBN (Print) | 9781108843508 |
DOIs | |
Publication status | Published - 2022 |
Externally published | Yes |
Keywords
- cost of dementia
- socio-economic gradient in dementia
- pharmaceutical research
- public financing of dementia care
- willingness-to-pay